Daicel Corporation (TYO:4202)

Japan flag Japan · Delayed Price · Currency is JPY
1,618.00
+18.00 (1.13%)
At close: Feb 12, 2026
Market Cap416.94B +17.2%
Revenue (ttm)578.81B +0.4%
Net Income41.14B -26.1%
EPS155.25 -23.2%
Shares Out257.69M
PE Ratio10.42
Forward PE8.70
Dividend60.00 (3.75%)
Ex-Dividend DateMar 30, 2026
Volume827,200
Average Volume926,980
Open1,600.00
Previous Close1,600.00
Day's Range1,595.50 - 1,618.00
52-Week Range1,057.50 - 1,618.00
Beta0.29
RSI77.32
Earnings DateFeb 5, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo... [Read more]

Sector Materials
Founded 1919
Employees 11,178
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4202
Full Company Profile

Financial Performance

In fiscal year 2025, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.

Financial Statements